Progress on growth promoting therapies other than growth hormone.
Zhejiang Da Xue Xue Bao Yi Xue Ban
; 51(4): 515-520, 2022 Aug 01.
Article
em En
| MEDLINE
| ID: mdl-37202099
ABSTRACT
Recombinant human growth hormone is a classical therapeutic drug for children with short stature. In recent years, as the mechanism of growth in children has been further explored, growth-promoting therapies other than growth hormone have made great progress. Recombinant human insulin-like growth factor (IGF)-1 is the main treatment for primary IGF-1 deficiency, and C-type natriuretic peptide (CNP) offers a therapeutic option for children with short stature due to chondrodysplasia. Growth hormone-releasing peptide analogues stimulate growth hormone release and may be used for growth-promoting therapy. In addition, gonadotropin-releasing hormone analogue (GnRHa) and aromatase inhibitors may delay the bone age in children and may be beneficial in improving final height. In this article, the research progress of growth-promoting therapies other than growth hormones is reviewed to provide more options for the clinical treatment of children with short stature.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hormônio do Crescimento
/
Hormônio do Crescimento Humano
Limite:
Child
/
Humans
Idioma:
En
Revista:
Zhejiang Da Xue Xue Bao Yi Xue Ban
Assunto da revista:
MEDICINA
Ano de publicação:
2022
Tipo de documento:
Article